ES2372187B8 - Procedimiento de identificación de animales vacunados frente a brucella. - Google Patents

Procedimiento de identificación de animales vacunados frente a brucella. Download PDF

Info

Publication number
ES2372187B8
ES2372187B8 ES200931101A ES200931101A ES2372187B8 ES 2372187 B8 ES2372187 B8 ES 2372187B8 ES 200931101 A ES200931101 A ES 200931101A ES 200931101 A ES200931101 A ES 200931101A ES 2372187 B8 ES2372187 B8 ES 2372187B8
Authority
ES
Spain
Prior art keywords
vaccinated animals
animals against
identification procedure
brucella
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200931101A
Other languages
English (en)
Other versions
ES2372187B1 (es
ES2372187A1 (es
Inventor
María Grilló Dolset
Beatriz Amorena Zabalza
Damián De Andrés Cara
Edgardo Moreno Robles
Esteban Chaves Olarte
Caterina Guzmán Verri
Carlos CHACÓN DÍAZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAC DE COSTA RICA UNA, University of
Universidad de Costa Rica
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Publica de Navarra
Original Assignee
NAC DE COSTA RICA UNA, University of
Universidad de Costa Rica
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Publica de Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200931101A priority Critical patent/ES2372187B8/es
Application filed by NAC DE COSTA RICA UNA, University of, Universidad de Costa Rica, Consejo Superior de Investigaciones Cientificas CSIC, Universidad Publica de Navarra filed Critical NAC DE COSTA RICA UNA, University of
Priority to EP10834263.5A priority patent/EP2508201A4/en
Priority to PE2012000760A priority patent/PE20121648A1/es
Priority to PCT/ES2010/070784 priority patent/WO2011067446A1/es
Priority to MX2012006303A priority patent/MX2012006303A/es
Priority to CN2010800630275A priority patent/CN102781468A/zh
Publication of ES2372187A1 publication Critical patent/ES2372187A1/es
Priority to CR20120301A priority patent/CR20120301A/es
Publication of ES2372187B1 publication Critical patent/ES2372187B1/es
Application granted granted Critical
Publication of ES2372187B8 publication Critical patent/ES2372187B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/23—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Brucella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procedimiento de identificación de animales vacunados frente a Brucella.#La presente invención se refiere al uso de una cepa de Brucella spp. que expresa la proteína Green Flourescent Protein (GFP) en la elaboración de medicamentos para la prevención de la brucelosis en mamíferos, a las vacunas frente a la brucelosis, y al método para la identificación de los mamíferos a los que se les ha administrado dichas vacunas. Preferiblemente, el método de la invención es un inmunoensayo, y aún más preferiblemente es un ensayo inmunoabsorbente ligado a enzimas (ELISA).
ES200931101A 2009-12-03 2009-12-03 Procedimiento de identificación de animales vacunados frente a brucella. Expired - Fee Related ES2372187B8 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES200931101A ES2372187B8 (es) 2009-12-03 2009-12-03 Procedimiento de identificación de animales vacunados frente a brucella.
PE2012000760A PE20121648A1 (es) 2009-12-03 2010-11-29 Procedimiento de identificacion de animales vacunados frente a brucella
PCT/ES2010/070784 WO2011067446A1 (es) 2009-12-03 2010-11-29 Procedimiento de identificación de animales vacunados frente a brucella
MX2012006303A MX2012006303A (es) 2009-12-03 2010-11-29 Procedimiento de identificacion de animales vacunados frente a brucella.
EP10834263.5A EP2508201A4 (en) 2009-12-03 2010-11-29 METHOD FOR IDENTIFYING ANIMALS VACCINATED AGAINST BRUCELLA
CN2010800630275A CN102781468A (zh) 2009-12-03 2010-11-29 用于鉴别接种对抗布鲁氏菌的疫苗的动物的方法
CR20120301A CR20120301A (es) 2009-12-03 2012-06-01 Procedimiento de identificación de animales vacunados frente a brucella

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931101A ES2372187B8 (es) 2009-12-03 2009-12-03 Procedimiento de identificación de animales vacunados frente a brucella.

Publications (3)

Publication Number Publication Date
ES2372187A1 ES2372187A1 (es) 2012-01-17
ES2372187B1 ES2372187B1 (es) 2012-11-26
ES2372187B8 true ES2372187B8 (es) 2013-04-29

Family

ID=44114638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200931101A Expired - Fee Related ES2372187B8 (es) 2009-12-03 2009-12-03 Procedimiento de identificación de animales vacunados frente a brucella.

Country Status (7)

Country Link
EP (1) EP2508201A4 (es)
CN (1) CN102781468A (es)
CR (1) CR20120301A (es)
ES (1) ES2372187B8 (es)
MX (1) MX2012006303A (es)
PE (1) PE20121648A1 (es)
WO (1) WO2011067446A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091308A1 (ru) 2017-11-24 2020-09-11 Консехо Супериор Де Инвестигасионес Сьентификас (Ксис) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
CN110863031A (zh) * 2019-09-29 2020-03-06 安徽医科大学第一附属医院 一种检测布鲁菌病治疗效果的标志物及其应用
CN111796091B (zh) * 2020-07-20 2023-09-08 天康生物制药有限公司 用于区分动物感染布氏杆菌或布氏杆菌菌影疫苗的试剂盒
WO2022271201A2 (en) * 2021-01-07 2022-12-29 International Advantage, Inc. Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054508A2 (en) * 2002-12-12 2004-07-01 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
CN101240290B (zh) * 2008-02-29 2011-06-15 杭州师范大学 一种含绿色荧光蛋白基因的植物转基因表达载体及其构建方法和应用
US20100226942A1 (en) * 2008-10-30 2010-09-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis
CN101586120B (zh) * 2009-07-15 2011-06-15 中国农业科学院哈尔滨兽医研究所 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体

Also Published As

Publication number Publication date
EP2508201A1 (en) 2012-10-10
PE20121648A1 (es) 2012-12-24
ES2372187B1 (es) 2012-11-26
EP2508201A4 (en) 2013-08-07
MX2012006303A (es) 2012-09-07
WO2011067446A1 (es) 2011-06-09
CR20120301A (es) 2013-02-27
ES2372187A1 (es) 2012-01-17
CN102781468A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
ECSP22046340A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
CR10298A (es) Metodos y composiciones para antagonismo de rage
GT200800269A (es) Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina
CL2012001650A1 (es) Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.
CL2008002727A1 (es) Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
CU20120095A7 (es) Antagonistas de pcsk9
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
ES2372187B8 (es) Procedimiento de identificación de animales vacunados frente a brucella.
BRPI1012924A2 (pt) derivados de amilóide p de soro e sua preparação e uso.
BRPI0914925A2 (pt) peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo
ECSP14020504A (es) Anticuerpos contra la metaloproteinasa de la matriz 9
CR10561A (es) Vacunas para malaria
BR112013013573A2 (pt) método para produzir anticorpos específicos para um antígeno de interesse, célula b isolada ou recombinante, população de anticorpo, e, anticorpo
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2372187

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20121126

FD2A Announcement of lapse in spain

Effective date: 20210915